Amgen Reports 9% Revenue Growth in Q2 2025 Driven by Key Product Sales
Company

Amgen Reports 9% Revenue Growth in Q2 2025 Driven by Key Product Sales

Sunshine Lake Pharma Makes History With Dual-Entity Restructuring Listing on HKEX
Others

Sunshine Lake Pharma Makes History With Dual-Entity Restructuring Listing on HKEX

NHSA Updates Volume-Based Procurement Policy for Medical Institutions in 11th VBP Tender
CompanyDrug

NHSA Updates Volume-Based Procurement Policy for Medical Institutions in 11th VBP Tender

Neowise Biotechnology's NW-101C Receives NMPA Clinical Trial Approval for PRAME-Targeted TCR-T Therapy
CompanyDrug

Neowise Biotechnology’s NW-101C Receives NMPA Clinical Trial Approval for PRAME-Targeted TCR-T Therapy

Dizal Pharma's DZD8586 Granted FDA Fast Track Designation for CLL/SLL Treatment
CompanyDrug

Dizal Pharma’s DZD8586 Granted FDA Fast Track Designation for CLL/SLL Treatment

AstraZeneca's Fasenra Approved for Pediatric Severe Eosinophilic Asthma in China
CompanyDrug

AstraZeneca’s Fasenra Approved for Pediatric Severe Eosinophilic Asthma in China

Sino Biopharmaceutical's Rovadicitinib Granted Breakthrough Therapy Designation for Chronic Graft-versus-Host Disease
CompanyDrug

Sino Biopharmaceutical’s Rovadicitinib Granted Breakthrough Therapy Designation for Chronic Graft-versus-Host Disease

Guangzhou Innogen Pharmaceuticals Launches H-Share Global Offering in Hong Kong
CompanyDeals

Guangzhou Innogen Pharmaceuticals Launches H-Share Global Offering in Hong Kong

BeOne Medicines Reports 42% Revenue Growth in Q2 2025 Driven by Brukinsa Sales
Company

BeOne Medicines Reports 42% Revenue Growth in Q2 2025 Driven by Brukinsa Sales

Sino Medical Sciences' COMETIU Stent System and COMEX Catheter Receive FDA Breakthrough Designation
CompanyMedical Device

Sino Medical Sciences’ COMETIU Stent System and COMEX Catheter Receive FDA Breakthrough Designation

Novartis Evaluates Acquisition of Avidity Biosciences to Strengthen Rare Disease Pipeline
CompanyDeals

Novartis Evaluates Acquisition of Avidity Biosciences to Strengthen Rare Disease Pipeline

Shanghai Issues New Measures to Boost Commercial Health Insurance for Biopharmaceutical Innovation
Policy / Regulatory

Shanghai Issues New Measures to Boost Commercial Health Insurance for Biopharmaceutical Innovation